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Resumo 
 
 O cancro da mama constitui a neoplasia com mais elevada taxa de incidência 
entre as mulheres portuguesas, sendo também a principal causa de morte por cancro no 
sexo feminino. O rastreio organizado, em implementação em Portugal para mulheres com 
idades compreendidas entre os 45 e os 69 anos, é uma das formas usadas para reduzir a 
mortalidade associada a este cancro. Contudo, existem ainda mulheres que não estão 
abrangidas por este meio de prevenção secundária, mulheres estas que recorrem ao 
rastreio oportunista ou apenas procuram ajuda médica quando apresentam já sintomas 
da doença. 
 O objetivo principal deste estudo consistiu em comparar as características clínico-
patológicas de tumores mamários de mulheres provenientes do rastreio organizado, 
rastreio oportunista e tumores sintomáticos, diagnosticados em 2011 e tratados no 
Instituto Português de Oncologia do Porto. Adicionalmente foram também avaliadas as 
diferenças nos tratamentos aplicados às pacientes.  
 Através da análise cuidada dos processos das pacientes, um total de 397 tumores 
malignos foram estudados no que concerne a: modalidade de diagnóstico, topografia, 
morfologia, grau de diferenciação, estadio, tratamentos aplicados, recetores hormonais, 
comorbilidades, estado de menopausa, hábitos tabágicos, Eastern Cooperative Oncology 
Group (ECOG) e índice de massa corporal. 
 As mulheres provenientes do rastreio organizado apresentaram tumores de 
menores dimensões (32,5% ≤ 10mm; rastreio oportunista: 16,9%; tumores sintomáticos: 
4,1%), estadios mais precoces (61,0% em estadio I; rastreio oportunista: 47,3%; tumores 
sintomáticos: 20,0%), maior percentagem de tumores bem diferenciados (30,9% tumores 
bem diferenciados; rastreio oportunista: 21,2% e tumores sintomáticos: 8,7%) e foram 
sujeitas a tratamentos menos agressivos (menor uso de quimioterapia adjuvante).  
 As diferenças encontradas nos tumores detetados pelo rastreio organizado, 
comparativamente aos tumores provenientes do rastreio oportunista e tumores 
sintomáticos, parecem indicar que o programa de rastreio populacional em 
implementação apresenta impacto favorável. É desejável que o impacto do presente 
programa de rastreio seja avaliado, utilizando modelos de estudos específicos, 
nomeadamente estudos populacionais. 
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Abstract 
 
 Breast cancer is the most frequently diagnosed cancer among Portuguese women, 
and is the leading cause of cancer death among womankind. Organized screening, like 
the one implemented in Portugal for women aged from 45 to 69 years, is used to reduce 
mortality rate associated with breast cancer. However, there still exist women who are not 
covered by this mean of secondary prevention. These women are monitored through 
opportunistic screening or they only search for medical help when they have symptoms of 
the disease. 
 The aim of this study was to compare the clinical and pathological features of 
breast tumours in women from the organized screening, opportunistic screening and 
symptomatic tumours diagnosed in 2011 and treated at the Portuguese Oncology Institute 
- Porto. In addition differences in the treatments applied to patients were also assessed. 
 Through careful analysis of the patients’ records, a total of 397 malignant tumours 
have been studied regarding: diagnostic modality, topography, morphology and degree of 
differentiation, stage, applied treatments, hormone receptors, co-morbidities, menopausal 
status, smoking habits, Eastern Cooperative Oncology Group (ECOG) and body mass 
index. 
 Women from the organized screening had smaller tumours (32.5% ≤ 10 mm; 
opportunistic screening: 16.9%; symptomatic tumours: 4.1%), earlier stages (61.0% in 
stage I, opportunistic screening: 47.3%; symptomatic tumours: 20.0 %), higher percentage 
of well-differentiated tumours (30.9% well-differentiated tumours, opportunistic screening: 
21.2% and symptomatic tumours: 8.7%) and underwent less aggressive treatments (less 
use of adjunctive chemotherapy). 
 The differences found in tumours detected through organized screening, compared 
to tumours from opportunistic screening or symptomatic tumours, seem to indicate that 
the implemented population screening program presents a favourable impact. It is 
desirable that the impact of the present screening programme is assessed, using specific 
study designs, namely population studies. 
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Introduction  
 
Epidemiology of Breast Cancer 
 Breast Cancer (BC) represents the most frequently diagnosed cancer among 
women worldwide (1-5), corresponding to about 1.67 million new cancer cases diagnosed 
during 2012. With a slightly higher number of new cases in less developed (883.000) than 
in more developed regions (788.000) (Figure 1), this malignancy is responsible for a high 
number of deaths, corresponding to the fifth cause of death from cancer overall (5). 
 
 
 
Figure 1 – Estimated breast cancer incidence worldwide in 2012 (5). 
 
  
 Consistent with worldwide trends, breast cancer represents the most frequently 
diagnosed cancer among Portuguese women associated with the highest mortality rate 
(Figure 2). Analysing both sexes, breast cancer is the most frequent cancer and the third 
cause of death from cancer overall (5, 6). 
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Figure 2 - Estimated age-standardised incidence and mortality rates among women (A) and both sexes 
(B) in 2012 in Portugal (5). 
 
 In the Northern Region, according to the Northern Region Cancer Registry 
(RORENO) data from 2009, breast cancer was the most commonly diagnosed cancer 
among women corresponding to 26.1% of the cancers diagnosed. In Portuguese 
Oncology Institute – Porto (IPO) more than 1200 new breast cancers were confirmed 
during 2011 (7). 
 
Histopathology 
 Breast alterations can be divided into three main groups: benign tumours, in situ 
tumours and invasive cancers (8). 
 Breast cancer is a heterogeneous group of diseases with different origins and 
natural histories (9-11). The majority of breast malignancies are developed from epithelial 
elements of the gland. More than 75% of cancers are ductal carcinomas, from 5-10% are 
lobular carcinomas (12) and the remaining are other types of carcinomas, which include 
medullary, mucinous and tubular carcinomas, among others (8). 
 The correct staging of this disease is essential for choosing adequate treatments 
and prognosis prediction (11, 13). The TNM staging includes information on tumour size 
(T) (Figure 3), regional lymph node metastasis (N) (Figure 4) and distant metastasis (M) 
(13). 
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Figure 3 - AJCC breast cancer staging – Primary tumour (T) (14). 
 
 
Figure 4 - AJCC breast cancer staging - Regional lymph nodes (N) (14). 
 
 Other tumour characteristics are also determinant, namely tumour grade, hormone 
receptors and biological biomarkers, among others (9-11, 13, 15). 
 Generally, tumours in early stages present better survival rates (16). 
 
Risk factors for Breast Cancer 
 Different elements are indicated as being major risk factors for developing breast 
cancer. Being a woman, increasing age and existence of familiar history of breast tumours 
represent the main factors (3, 13, 17, 18). 
 The occurrence of previous benign breast alterations (13, 18), breast density (19-
22), diet and lifestyle (2, 13, 18, 23) and reproductive and hormonal factors (2, 3, 13, 17, 
18) are also described as risk factors. 
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Breast Cancer Treatments 
 Breast malignancies are usually treated through combinations of different 
therapies, such as surgery, chemotherapy, hormone therapy and radiotherapy. Choosing 
the most appropriate treatment depends on several tumour characteristics (stage at 
diagnosis and histological grade), biology (biomarkers and gene expression) and personal 
features and choices (age at diagnosis, comorbidities and personal preferences) (9-11, 
13, 15). 
 For example, tumours in early stages usually require less aggressive treatments or 
combinations of treatments when compared to tumours in more advanced stages (13, 15). 
 
Breast Cancer Screening Programme 
 The main aim of a screening program is to allow the detection of a disease at an 
early stage among those who were apparently healthy, with the expectancy that a more 
effective treatment can be applied at an earlier stage (1, 4, 13, 15, 16, 24-28). Screening 
programs must follow some criteria, first implemented by Wilson and Jungner in 1968 
(29), but still currently used, namely: 
- The screened condition should constitute an important health problem; 
- There should be an applicable treatment for patients with confirmed disease; 
- Facilities for diagnosis and treatment must be available; 
- A recognizable early symptomatic stage should exist; 
- There should be a suitable test or examination, acceptable to the population; 
- The natural history of the condition should be understood; 
- There should be an agreed policy on whom to treat as patient; 
- The cost of case-finding should be economically balanced; 
- Case-finding should be a continuous process and not a once and for all project 
(Wilson JMG and Jungner G, 1968) (16, 29). 
 In general, breast cancer screening meets these criteria. Implemented primarily in 
Centre Region, organized Breast Cancer Screening Programme (BCSP) was firstly used 
in 1990 (30, 31), later implemented in Southern Region in 1997, Northern Region and 
Madeira in 1999, Algarve in 2005 and Acores in 2009 (31). 
 According to the lists of registered users of Health Centres, women aged between 
45-69 years are invited by letter to a bilateral mammography with two views, which is a 
sensitive (77% to 95%) and specific (94% to 97%) exam easily applicable to the majority 
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of women (32). The mammography is analysed by two experienced Radiologists (double 
blind reading) and each Radiologist attributes a score in a pre-defined scale, which is in 
accordance with European Guidelines. If these readings point to a doubtful or positive 
result or in case of discrepancies in the results obtained, a third reading will be performed 
by another Radiologist. Positive screening results are analysed by a multidisciplinary team 
composed by a Radiologist, a Surgeon and a Pathologist, and the most appropriate 
monitoring and treatments are established according to hospital standardized protocols 
(13,30). 
 Mammography is the gold standard of screening, but although its effectiveness is 
proved for women between 50-69 years, its use remains controversial for younger ages 
(1, 33). Young women breasts have higher density which compromises the visualization 
and interpretation of injuries through this method. For these cases, ultrasonography may 
be a useful and complementary resource (1, 13). 
 The use of other diagnostic exams like magnetic resonance imaging (MRI) is also 
discussed in literature once it presents better sensitivity, especially in young women. 
However, this procedure has more false positive recalls and is substantially more 
expensive; currently this exam is mainly used for doubtful cases, validated cases of 
genetic risk and follow-up of some previous tumours (1, 13, 34). 
 In Portugal organized breast cancer screening programme is applied to women 
aged between 45-69 years through mammographic examination. In 2011, according to 
Northern Health Regional Administration (ARS-N) (31), 12 of the 24 health centre groups 
of Northern region had implemented organized screening. With a geographical coverage 
of 49.5%, over 118.000 women were invited to attend mammography but only 62.186 
were screened (compliance rate of 52.6%). 
 According to the literature, in order to ensure the quality and effectiveness of the 
screening program, the rate of participation must be at least 70% (35). Although 
competing with the major goal of high participation rates, it is extremely important to clarify 
the woman about the advantages and disadvantages of participation in screening. This 
women’s “informed choice” is considered of utmost importance. The benefit of early 
detection of cancer, leading to less mutilating treatments, must be properly balanced with 
inherent risks of screening (16). For instance, Brodersen et al. (36) argues that a woman 
with a false positive result experiences psychological damage for at least three years after 
the wrong result. 
 Opportunistic screening constitutes the type of screening performed when 
someone goes to its medical assistant for routine without specific complaints and is 
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submitted to complementary exams that may allow diagnosis of a condition or a 
previously unknown pathology. Generally, this procedure isn’t subjected to any external 
control, being only dependent on the medical assistant recommendations (16). 
 The greater objective of screening is to detect cancer before it becomes clinically 
evident, believing that if a cancer is diagnosed earlier then treatments will be less 
aggressive and more effective (1, 4, 15, 16, 24-28, 34, 37). However, some screen-
detected tumours may never progress to become clinically detectable and some women 
would die for other reasons before the cancer could be clinically evident. This fact, known 
as overdiagnosis, constitutes the major harm of screening and refers to all cancers, 
invasive or in situ (1, 16, 24, 25, 33). 
 It is accepted that tumours grow at variable rates and some screen-detected 
cancers may progress so slowly that they would never have been presented clinically. 
Furthermore, some tumours may remain stable or even regress with time, nevertheless 
they are equally treated. Thus, these women will undergo unnecessary treatments which 
may result in adverse effects in their quality of life (1, 16, 24, 25, 33, 38). 
 Overdiagnosed cancers have a greater tendency to be ductal carcinomas in situ 
(DCIS) and possibly tend to be low/intermediate grade rather than high grade (24). 
 Whether a particular woman has had an overdiagnosed cancer cannot be 
determined, being only possible to estimate the frequency of overdiagnosis (1, 16, 24, 25, 
33). 
 The existence of false positive results, defined as women that were recalled and 
considered not having cancer, is the most commonly adverse effect found in 
mammographic screening. Recalled women can only have further imaging exams or be 
biopsied, under local or general anaesthesia. False positive results can have a powerful 
psychological impact on women (1, 16, 24, 25, 34). 
 Other harms can be associated to breast cancer screening, namely, the radiation 
exposure during mammography, pain during the breast examination, possibility of false-
negative results, psychological consequences, morbidity and mortality associated to 
treatments (1, 16, 24). 
 Interval cancers, defined as tumours diagnosed after a negative mammographic 
exam and before the following planed, constitute an indicator of the quality of 
mammographic examination (1, 39). Since this type of tumours can’t be totally eliminated, 
they must be reduced as much as possible. When a women has a diagnosis of an interval 
cancer the previous imaging exams must be reviewed to determine if the alteration 
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existed in the previous screening, if so this case is classified as a true false-negative 
result (1). 
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Aims 
 The aim of this study was to compare clinicopathological characteristics of invasive 
breast tumours of women from organized screening (LPCC screening), opportunistic 
screening and symptomatic tumours, diagnosed in 2011 and treated exclusively at the 
Portuguese Oncology Institute - Porto. 
 Additionally, it was intended to verify if variations among these groups can end up 
having differences in the patients’ treatment. 
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Materials and Methods 
 Invasive breast cancers diagnosed during 2011 in women aged between 45-69 
years, with no malignant pre-existing tumours, and treated entirely in IPO, were registered 
at RORENO. The list of cases fulfilling the criteria was retrieved from RORENO and 
information on the variables under study was gathered directly from the patients’ records, 
by one person only, double-checked and in doubtful cases reviewed by experts. Data 
concerning the pathological anatomy of tumours was directly collected from reports. 
Through the examination of patient´s processes three main groups were created: LPCC 
screening, Opportunistic screening and Symptomatic tumours. 
 LPCC screening tumours refer to a group of women invited by letter to a 
mammographic exam every two years, in mobile units, with a histologically confirmed 
subsequent diagnosis of breast cancer. These women must attend the examination 
without any sort of symptoms. 
 Opportunistic screening constitutes the type of screening performed when 
someone goes to its medical assistant for routine without specific complaints and is 
submitted to complementary exams that may allow diagnosis of a condition or a 
previously unknown pathology. Generally, this procedure isn’t subjected to any external 
control, being only dependent on the medical assistant recommendations. Women from 
this group do not present any symptoms as well. 
 The last group named Symptomatic tumours is composed of women seeking 
medical care due to at least one complain. Reported symptoms/signs were: palpable 
nodule, changes in size and shape of the breast, breast exudate, pain and nipple 
inversion, among others. Women were included in this group regardless their participation 
or not in any kind of screening. 
 Variables under analysis included: 
- Date of birth; 
- Diagnostic mode (LPCC screening, Opportunistic screening or Symptomatic 
tumours); 
- Topography and morphology according to the International Classification of 
Diseases for Oncology – 3rd edition (tumours were divided in three different 
groups: ductal carcinomas (which only include pure ductal tumours), lobular 
carcinomas (which contain lobular carcinomas, mixed ductal and lobular 
carcinomas and mixed lobular and other types of carcinomas) and other tumours 
 Materials and Methods 
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(which comprises all other types of tumours like: medullary, mucinous and tubular 
carcinomas, among others); 
- Histological grade in accordance with the Nottingham Grading System (40); 
- Comorbidities (myocardial infarction, congestive heart failure, cerebrovascular 
disease, dementia, chronic obstructive pulmonary disease, among others, 
assessed as a whole using the Charlson Index); 
- Laterality and multifocality of the tumour; 
- Menopausal status (When this information was missing women over 50 years 
were considered post-menopausal); 
- Smoking habits; 
- Body Mass Index (BMI) according to the World Health Organization (WHO) 
International Classification of adult underweight (BMI<18.5kg/m2), normal (BMI: 
18.5-24.9kg/m2), overweight (BMI: 25.0-29.9kg/m2) and obesity (BMI≥30.0kg/m2) 
(41); 
- ECOG Performance status; 
- Diagnostic exams; 
- Clinical and pathological stages at diagnosis according to American Joint 
Committee on Cancer’s (AJCC) TNM classification (14) (Where applicable, 
tumours in stage IA and IB were considered tumours in early stages. The 
remaining stages II, III and IV were considered advanced stages); 
- Tumour size (three cut-offs were used in accordance with the cut-offs of the 
European Guidelines (35)); 
- Hormonal status (Oestrogen Receptors (ER), Progesterone Receptors (PR), 
Human Epidermal growth factor Receptor 2 (HER2)); 
- Proliferation index evaluation through ki67; 
- Treatments applied (surgery, chemotherapy, hormone, radiotherapy, targeted 
therapy). 
 Proportions of the three groups of interest were compared, through pairwise 
comparisons, using X2 test or Fisher’s exact test and one-way analysis of variance was 
used for continuous variables. Differences were considered statistically significant for P 
<0.05. 
 Unconditional multivariate logistic regression was applied to evaluate the 
association between diagnostic modality and clinicopathological and personal 
characteristics of tumours adjusted for possible confounding factors. 
 Materials and Methods 
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 One model, including stage, tumour grade, pathological diameter, triple negative 
receptors, Charlson Index, BMI, age interval and treatments schemes, was tested to 
compare LPCC screening tumours with symptomatic tumours. 
 To the comparison between LPCC screening tumours with opportunistic screening 
tumours one model was tested including stage, pathological tumour size, Charlson Index, 
treatment schemes and age.  
 Comparing Symptomatic tumours and Opportunistic screening tumours, one model 
was tested including pathological tumour size, tumour grade, stage at diagnosis, age 
interval and treatments schemes. 
 Differences considered statistically significant for P<0.05. 
 All data were collected and analysed with proper authorization of the ethics’ 
commission of IPO. 
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Results 
 According to RORENO data, 1297 invasive breast cancers were registered in IPO 
with a diagnosis during 2011. Only 796 cases occurred in women aged between 45-69 
years (screening interval) and one of these had no cytological/histological confirmation. A 
total of 774 had no previous malignancy and 78 of these were excluded because of lack of 
diagnostic modality information. The exclusion criteria are explained in Figure 5. At the 
end, 397 tumours were included in this study since the rest of the cases had previous 
treatments in other institutions, which could contribute to bias. 
 Regarding the diagnostic mode, 107 women (27.0%) presented symptoms at 
diagnosis, 123 (31.0%) were referred by LPCC screening and 167 (42.1%) were sent by 
opportunistic screening.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Invasive breast cancers 
diagnosed in 2011 (n=1297) 
Excluded (n=900): 
 
- 501 women out of the age range; 
- 1 without laboratorial confirmation; 
- 21 with previous malignancies; 
- 78 with lack of diagnostic modality; 
- 299 with previous treatments. 
397 invasive breast cancers 
LPCC screening 
(n=123) 
Opportunistic screening 
(n=167) 
Symptomatic tumours 
(n=107) 
Figure 5 - Diagram of the study sample selection. 
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* Percents were calculated excluding cancers with unknown values; LS/ST, LPCC screening tumours compared to 
Symptomatic tumours; LS/OP, LPCC screening tumours compared to Opportunistic screening tumours; ST/OP, 
Symptomatic tumours compared to Opportunistic screening tumours; BMI, body mass index. 
Variable LPCC Screening Symptomatic Tumour Opportunistic Screening P value P value P value
(LS) (ST) (OP)
value n=123 (%*) n=107 (%*) n=167 (%*) LS/ST LS/OP ST/OP
Age Group 45-49 26 (21.1) 23 (21.5) 41 (24.6) 0.001 0.02 0.33
50-59 35 (28.5) 54 (50.5) 69 (41.3)
60-69 62 (50.4) 30 (28.0) 57 (34.1)
BMI Low weight / Healthy 29 (24.6) 45 (45.0) 48 (31.6) 0.003 0.18 0.09
Preobesity 41 (34.7) 32 (32.0) 58 (38.2)
Obesity 48 (40.7) 23 (23.0) 46 (30.3)
Missing 5 7 15
Smoking habits Never 105 (86.8) 83 (80.6) 126 (78.8) 0.18 0.16 0.73
Yes, previously 10 (8.3) 8 (7.8) 17 (10.6)
Yes, currently 6 (5.0) 12 (11.7) 17 (10.6)
Missing 2 4 7
Menopausal Status Postmenopausal 89 (72.4) 69 (64.5) 115 (68.9) 0.25 0.60 0.54
Pre/perimenopausal 34 (27.6) 38 (35.5) 52 (31.1)
Comorbidities Yes 84 (68.3) 56 (52.3) 92 (55.1) 0.02 0.03 0.75
(Charlson index) No 39 (31.7) 51 (47.7) 75 (44.9)
ECOG Performance Asymptomatic 115 (95.8) 96 (93.2) 152 (94.4) 0.57 0.79 0.89
Status Symptomatic 5 (4.2) 7 (6.8) 9 (5.6)
Personal Characteristics Diagnostic Mode Significance Level
 The different personal characteristics of women are summarized in Table 1. Some 
of the studied variables such as smoking habits, menopause status and general status of 
the patient (ECOG) demonstrated to be similar among the different groups. 
 Assessing age at diagnosis it was found that women from LPCC screening were 
significantly older than women from the other two groups (P=0.001 for symptomatic 
tumours and P=0.02 for opportunistic screening tumours). Ages of women from 
opportunistic screening and symptomatic tumours had no statistically significant 
differences (P=0.33). 
 Women belonging to LPCC screening group were significantly fatter than those 
from symptomatic tumours group (P=0.003). BMI was similar between LPCC and 
opportunistic screening groups and between symptomatic and opportunistic screening 
groups. 
 Concerning comorbidities, assessed through Charlson Index, women from LPCC 
screening had a higher proportion of comorbidities when compared to symptomatic and 
opportunistic screening tumours (P=0.02 and P=0.03, respectively). For this variable, 
symptomatic and opportunistic tumours had no statistically significant differences. 
 
Table 1 - Personal characteristics of invasive breast cancers from LPCC screening, Opportunistic 
screening or Symptomatic tumours diagnosed in 2011 and treated exclusively at IPO.  
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 The main clinicopathological characteristics of the three groups are summarized in 
Table 2. The most commonly found subtype was ductal carcinoma, at similar proportions 
between study groups. Among all groups there were no statistically significant differences 
with regard to multifocality, with the majority of tumours emerging as a single node. 
 With respect to pathological tumour size 32.5% of tumours from LPCC screening 
presented 10mm or less, 53.5% less than 15mm and 72.8% 20mm or less. For tumour 
diameter of 10mm statistically significant differences were found between the three groups 
(P<0.001 LPCC screening versus symptomatic tumours (LS/ST); P=0.005 LPCC 
screening versus opportunistic screening (LS/OP); P=0.01 symptomatic tumours versus 
opportunistic screening (ST/OP)), wherein symptomatic and opportunistic tumours exhibit 
greater dimensions. For the remaining comparisons (15mm and 20mm) no statistically 
significant differences were found between LPCC screening tumours and opportunistic 
screening tumours and it was found that LPCC screening tumours were significantly 
smaller than symptomatic and opportunistic screening tumours (P<0.001 for LS/ST; 
P=0.004 and P<0.001 for ST/OP). 
 Regarding tumour grade, LPCC screening tumours were better differentiated with 
30.9% of the tumours being well differentiated, 48.8% moderately differentiated and 
20.3% poorly differentiated. Symptomatic tumours emerge significantly poorer 
differentiated being 35.6% poorly differentiated, 55.8% moderately differentiated and 8.7% 
well differentiated (P<0.001). Amongst symptomatic tumours and tumours from 
opportunistic screening the same tendency was found with symptomatic tumours being 
less differentiated (P=0.02). No statistically significant differences were found between 
LPCC and opportunistic screening tumours. 
 No tumour from LPCC and opportunistic screening showed distant metastasis at 
diagnosis, existing no differences between these groups. On the other hand 8.5% of 
symptomatic tumours exhibited distant metastasis at the date of diagnosis thus existing 
statistically differences between these and LPCC and opportunistic screening tumours 
(P=0.001 and P<0.001, respectively). 
 Concerning the stage at diagnosis, LPCC screening tumours were found in earlier 
stages with 61% of them being in stage I. Less proportion of tumours from opportunistic 
screening were in stage I (47.3%) however this difference wasn´t statistically significant. In 
comparison with symptomatic tumours both had significantly earlier stages (P<0.001 for 
both) with only 20% of symptomatic tumours in stage I. 
 For Oestrogen Receptors LPCC screening tumours were positive in a slightly 
increased proportion (90.2%) compared to 87.3% for opportunistic tumours and 80.4% for 
Results 
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symptomatic tumours, however there were only statistically significant differences 
between LPCC screening tumours and symptomatic tumours (P=0.03). For Progesterone 
Receptors the results were similar among the three groups in study. 
 A substantial number of missing values was found in the HER2 analysis in the 
three groups. Nevertheless, there was a significantly higher proportion of negatives in 
LPCC screening tumours (85.8%) and opportunistic tumours (83.4%) compared to 
symptomatic tumours (69.7%) (P=0.005 and P=0.02, respectively). 
 Triple negative tumours showed higher proportion in symptomatic tumours, being 
statistically significant the difference when compared to LPCC screening tumours 
(P=0.04). 
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Clinicopathological
Characteristics
Variable LPCC Screening Symptomatic Tumour Opportunistic Screening P value P value P value
(LS) (ST) (OP)
value n=123 (%*) n=107 (%*) n=167 (%*) LS/ST LS/OP ST/OP
Histology Ductal 88 (71.5) 79 (73.8) 122 (73.1) 0.93 0.86 0.90
Lobular 20 (16.3) 16 (15.0) 28 (16.8)
Others 15 (12.2) 12 (11.2) 17 (10.2)
Multifocality No 97 (79.5) 81 (77.1) 129 (78.7) 0.79 0.98 0.89
Yes 25 (20.5) 24 (22.9) 35 (21.3)
Missing 1 2 3
Pathological ≤10 mm 37 (32.5) 3 (4.1) 26 (16.9) <0.001 0.005 0.01
Tumour Size >10 mm 77 (67.5) 71 (95.9) 128 (83.1)
Missing 5 7 5
<15 mm 61 (53.5) 17 (23.0) 67 (43.5) <0.001 0.13 0.004
≥15 mm 53 (46.5) 57 (77.0) 87 (56.5)
Missing 5 7 5
≤20 mm 83 (72.8) 29 (39.2) 106 (68.8) <0.001 0.57 <0.001
>20 mm 31 (27.2) 45 (60.8) 48 (31.2)
Missing 5 7 5
Tumour Grade Grade 1 38 (30.9) 9 (8.7) 35 (21.2) <0.001 0.15 0.02
Grade 2 60 (48.8) 58 (55.8) 87 (52.7)
Grade 3 25 (20.3) 37 (35.6) 43 (26.1)
Missing 0 3 2
Stage I 75 (61.0) 21 (20.0) 78 (47.3) <0.001** 0.07 <0.001
II 32 (26.0) 42 (40.0) 58 (35.2)
III 16 (13.0) 33 (31.4) 29 (17.6)
IV 0 (0) 9 (8.6) 0 (0)
Missing 0 2 2
ER status Positive 111 (90.2) 86 (80.4) 145 (87.3) 0.03 0.56 0.16
Negative 12 (9.8) 21 (19.6) 21 (12.7)
Missing 0 0 1
PR status Positive 93 (76.2) 73 (69.5) 127 (77.0) 0.26 1.00 0.22
Negative 29 (23.8) 32 (30.5) 38 (23.0)
Missing 1 2 2
HER2 status Negative 91 (85.8) 69 (69.7) 121 (83.4) 0.005 0.73 0.02
Positive 15 (14.2) 30 (30.3) 24 (16.6)
Missing 17 8 22
Triple Negative No 116 (95.9) 95 (88.8) 151 (93.2) 0.04 0.48 0.30
Yes 5 (4.1) 12 (11.2) 11 (6.8)
Missing 2 0 5
Significance LevelDiagnostic Mode
Table 2 - Clinicopathological characteristics of invasive breast cancers from LPCC screening, 
Opportunistic screening or Symptomatic tumours diagnosed in 2011 and treated exclusively at IPO.  
 
  
 
 
* Percents were calculated excluding cancers with unknown values; ** 25.0% of cells expected a count lower than 5; 
LS/ST, LPCC screening tumours compared to Symptomatic tumours; LS/OP, LPCC screening tumours compared to 
Opportunistic screening tumours; ST/OP, Symptomatic tumours compared to Opportunistic screening tumours; ER, 
oestrogen receptors; PR, progesterone receptors; HER2, epidermal growth factor receptor 2. 
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Variable LPCC Screening Symptomatic Tumour Opportunistic Screening P value P value P value
(LS) (ST) (OP)
value n=123 (%*) n=107 (%*) n=167 (%*) LS/ST LS/OP ST/OP
Type of treatment Surgery / Surgery + other 119 (96.7) 76 (71.0) 159 (95.2) <0.001 0.72 <0.001
QT / QT + other 4 (3.3) 31 (29.0) 8 (4.8)
Treatment schemes Surgery+others 64 (53.8) 9 (12.3) 47 (29.9) <0.001 <0.001 0.006
Surgery+QT+others 55 (46.2) 64 (87.7) 110 (70.1)
Treatments Diagnostic Mode Significance Level
 Different therapeutic schemes were applied when treating women from the 
different groups (Table 3). Women from LPCC screening underwent a higher proportion of 
surgeries as first treatment (96.7%). The same occurred with women from opportunistic 
screening (95.2%). From women with symptoms at diagnosis only 71% attended surgery 
firstly, existing thus statistically significant differences between this group and the others 
(P<0.001). For women in which surgery was used as first treatment, LPCC screening 
women underwent significantly decreased use of chemotherapy as adjuvant therapy 
(46.2% compared to 87.7% for symptomatic tumours and 70.1% for opportunistic 
tumours). All groups showed statistically significant differences (P<0.001 LS/ST and 
LS/OP; P=0.006 ST/OP). 
 
Table 3 - Treatments applied to women with invasive breast cancers diagnosed in 2011 and treated 
exclusively at IPO. 
  
 
  
 Through unconditional multivariate logistic regression the association between 
diagnostic modality and clinicopathological and personal characteristics of tumours 
adjusted for possible confounding factors was tested. 
 When testing LPCC screening tumours versus symptomatic tumours the final 
model included pathological diameter, stage at diagnosis and BMI. LPCC tumours were 
smaller, with earlier stages and women were fatter. 
 For LPCC screening tumours versus opportunistic screening tumours, pathological 
tumour size was the unique feature in the final model.  
 Regarding symptomatic tumours versus opportunistic screening tumours testing, 
the final model included pathological tumour size, stage at diagnosis and BMI. More 
advanced stages and higher pathological diameters presented higher chance of being 
* Percents were calculated excluding cancers with unknown values; LS/ST, LPCC screening tumours compared to 
Symptomatic tumours; LS/OP, LPCC screening tumours compared to Opportunistic screening tumours; ST/OP, 
Symptomatic tumours compared to Opportunistic screening tumours. 
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part of the symptomatic tumours group and higher BMI with greater chance of coming 
from opportunistic screening. 
 
Table 4 - Multivariate logistic regression for the association between clinicopathological 
characteristics of breast cancers and diagnostic modality. Three models comparing pairwise the three 
studied groups. 
  
 
  
 
OR adjusted for covariates 95% confidence interval P value
Variable
value
Model 1 - LPCC/ST* (n=184)
Pathological diameter ≤10mm 1
>10mm 0.13 0.03-0.61 0.01
Body Mass Index Low weight / Healthy 1
Preobesity 1.87 0.85-4.10 0.12
Obesity 2.90 1.29-6.52 0.01
Stage Early stages 1
Advanced stages 0.37 0.18-0.76 0.007
Model 2 - LPCC/OP** (n=249)
Pathological diameter ≤10mm 1
>10mm 0.49 0.27-0.89 0.02
Model 3 - ST/OP*** (n=213)
Pathological diameter ≤10mm 1
>10mm 4.93 1.07-22.72 0.04
Body Mass Index Low weight / Healthy 1
Preobesity 0.44 0.22-0.89 0.02
Obesity 0.42 0.20-0.90 0.02
Stage Early stages 1
Advanced stages 2.32 1.19-4.54 0.01
OR, odds ratio; *LPCC/ST, LPCC screening tumours compared to Symptomatic tumours; **LPCC/OP, LPCC screening 
tumours compared to Opportunistic screening tumours; ***ST/OP, Symptomatic tumours compared to Opportunistic 
screening tumours. 
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Discussion 
 In this study a comparison of three groups of breast cancers (tumours arising from 
organized screening, tumours from opportunistic screening and symptomatic tumours) 
diagnosed in women during 2011 and treated in IPO was performed. This evaluation was 
carried out trying to draw conclusions about the potentially imposed differences by 
different diagnostic modalities. It was found that women from organized LPCC screening 
had significantly smaller tumours than the symptomatic group, better differentiated, at 
lower stages, with a higher percentage of positivity for oestrogen receptor and a larger 
amount of negativity for HER2 receptor and triple negative tumours. Compared to 
opportunistic screening tumours, significant differences were found for tumours with 10 
mm or less, being LPCC screening tumours smaller. 
 Through the research of patients’ records it wasn’t possible to distinguish if 
cancers were detected in initial or in subsequent screenings or if the cases corresponded 
to interval cancers. The main limitation of this study comes from the fact that it is hospital 
based, therefore it doesn’t provide the complete scope of participation in breast cancer 
screening modality and its results. Furthermore, the reduced number of cases might have 
impaired some of the results. 
 A tumour is considered clinically palpable when it has one cm or more (42). In this 
study, over thirty per cent of LPCC tumours presented a size smaller than one cm making 
the tumour unreachable at palpation. For tumours from opportunistic screening this 
percentage was lower prowling seventeen per cent of the cases. As expected, almost all 
symptomatic tumours presented sufficient size to be felt through breast palpation. The 
remaining symptomatic tumours showed other symptoms as skin alterations, breast 
enlargement, nipple changes and pain, among others. 
 Considering the histological tumour type, the distribution of tumours was similar 
among the three groups of interest. According to the literature, earlier stages are an 
expected result of adherence to organized population-based screening programs (15, 38). 
In line with the predictable (38, 43), LPCC screening tumours and opportunistic screening 
tumours presented earlier stages comparing to symptomatic tumours. 
 Other variables related to early cancer detection like tumour size and grade were 
also analysed. According with the expected, LPCC screening tumours were smaller and 
better differentiated which was reflected in the treatments applied (4, 26, 27, 37, 38). This 
group of tumours required less aggressive treatments and has been subjected to less use 
of chemotherapy in association with other therapeutics which is in accordance with the 
desired (15, 43). 
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 Triple negative tumours, described in literature as having an inherently aggressive 
disease phenotype (9, 11), were as expected more frequent in the symptomatic tumours 
group. For this type of tumours no specific treatment is known yet (9, 11). 
 HER2 positive tumours, more common in the symptomatic tumours group, are 
known to possess an aggressive disease phenotype as well but, in contrast with triple 
negative tumours, there have been introduced HER2 targeted therapies. With these 
therapies patients with HER2 positive tumours no longer have a worse prognosis than the 
negative ones (9, 11, 15). 
 Symptomatic tumours evaluated in this study were worse differentiated, with higher 
stages and having even metastasis at diagnosis, as expected (26, 38). These 
malignancies emerged mainly in women healthy or underweight. 
  In general, obesity is positively associated with risk of breast cancer development 
mainly in post-menopausal women and possibly in pre-menopausal ones considering 
breast density. This risk factor is also associated with worse prognosis (2). BMI has also 
been associated with the women’s participation in population screening, relating women 
with higher BMI usually as non-attenders of organized screening when compared with 
women with lower BMI.  Hellmann et al. (44) found an association between obesity and 
non-participation in screening among Danish women. The same association was 
described previously in US, where opportunistic rates were higher in obese women (44) 
compared to organized screening rates. The results observed in our study are in 
disagreement with the previous findings, as the women that were in the LPCC screening 
group had a higher BMI than the women in the symptomatic group. Possible explanations 
for these results would require further BMI analysis of the population from which these 
women were originated; also, the socio-economic status of these women can have an 
impact on BMI. 
 Mammographic density, which might impair tumour detection, is according to 
literature, inversely associated with body mass index (44, 45). Applying this finding to the 
results obtained in this study this would mean that LPCC screening women, which had 
higher body mass index, would have less dense breasts. 
 In the aforementioned study in Danish women, the existence of diabetes was also 
reported as a barrier to screening, although this finding was not statistically significant due 
to the limited number of cases (44). In the present study no statistically significant 
differences were found when comparing the different groups in relation to diabetes with or 
without organ damage. 
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 In general, therapeutic schemes applied were substantially different in terms of 
aggressiveness among the three study groups. LPCC screening tumours were mostly 
treated through the use of surgery alone or together with other treatment options like 
radiotherapy and hormone therapy (53.8%). Opportunistic screening tumours underwent 
more aggressive treatments; in 70.1% chemotherapy was added. Finally, symptomatic 
tumours were treated in 87.7% of the cases with surgery and chemotherapy combined or 
not with other treatment options. The fact that symptomatic tumours were subjected to 
more aggressive and mutilating treatments is in line with the expected as these cases 
were in more advanced stages, corroborating that screening contributes to the earlier 
detection of tumours, culminating in a less need for treatments (15). 
 Interestingly, although tumour stages evaluated as initial or advanced weren’t 
significantly different between organized and opportunistic screening, this last group of 
women underwent significantly more chemotherapy combined with surgery. Even after 
stratifying for the presence or absence of comorbidities, women from the opportunistic 
screening experienced chemotherapy more frequently. 
 The association between diagnostic modality and personal and clinicopathological 
characteristics of the cases was evaluated through unconditional multivariate regression 
adjusting for possible confounding factors. For LPCC screening versus opportunistic 
screening, pathological tumour size was the unique feature in the final model significantly 
different in these two groups. This tumour characteristic is possibly the main reason for 
the differences in treatments discussed above. 
 Through general analysis of the results of this study it can be accepted that 
opportunistic screening presents similar efficiency to LPCC screening in the early 
detection of cancer, however it implies disadvantages, mainly economics. The recurrent 
and simultaneous use of mammography and ultrasonography as well as reduced time 
intervals between exams carries unnecessary costs to the health system. According to 
ARS-N in 2007 and 2008 over 16% of women repeated screening mammography and 
59% attended additional breast ultrasound, as a result of opportunistic screening (46). 
 Organized breast cancer screening programme allows a higher coverage of the 
population and a reduction in the number of exams performed, without compromising its 
quality, making it an intervention with higher cost-effectiveness. Tumours are detected 
mainly in early stages contributing to reduce aggressive and mutilating treatments. Lastly, 
with more initial stages and efficient treatments it is expected that breast cancer mortality 
will be significantly lower in the future. 
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Conclusion and Future Perspectives 
 The question “is screening having an impact?” was rhetoric. It cannot be answered 
in a valid and conclusive way with a cross-sectional study like the one presented here. 
The question just pointed a way. Specifically designed studies have to be performed. 
There are clear guidelines on what to do. In the end, answering the question will be done 
using critical appraisal, judging on the evidence available in several written reports and 
different types of published studies. Within that process, this study will be no doubt 
assessed. Data here collected and corresponding analysis is compatible with the 
hypothesis that the existing organized screening program is resulting in more favourable 
(for prognosis) breast cancers being diagnosed and less aggressive treatment strategies 
performed. Differences with symptomatic tumour cases and those diagnosed during 
opportunistic screening are clear. Findings are compatible with an effective screening 
program but cannot prove it. 
 Just increasing the sample size could be useful. Meanwhile, this study would be 
enriched with the analysis of some additional features such as the existence of previous 
breast benign or in situ tumours or familiar history of breast malignancies. Additionally, the 
evaluation of socio-economic status, obtained for example by education level information, 
could contribute to a better understanding of the influence of socio-economic factors in the 
screen modality choice. Using the subjects of this study in case-control could be one more 
step in the right direction.  
 Performing the recommended analytical epidemiology studies that can answer the 
question “is screening having an impact?” is the desirable future.  
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Attachments 
AJCC´s Breast Cancer TNM Staging 
 
 
 
Primary tumour Characteristics
TX Primary tumour cannot be assessed
T0 No evidence of primary tumour
Tis Carcinoma in situ
T1mi Tumour ≤ 1mm in greatest dimension
T1a Tumour > 1mm but ≤ 5mm in greatest dimension
T1b Tumour > 5mm but ≤ 10mm in greatest dimension
T1c Tumour > 10mm but ≤ 20mm in greatest dimension
T2 Tumour > 20mm but ≤ 50mm in greatest dimension
T3 Tumour > 50mm in greatest dimension
T4a Extension to the chest wall, not including only pectoralis muscle adherence / invasion
T4b
Ulceration and / or ipsilateral satellite nodules and / or edema (including peau d’orange) of the skin,
which do not meet the criteria for inflammatory carcinoma
T4c Both T4a and T4b
T4d Inflammatory carcinoma
cN Characteristics
cNX Regional lymph nodes cannot be assessed (for example, previously removed)
cN0 No regional lymph node metastases
cN1 Metastases to movable ipsilateral level I, II axillary lymph node(s)
cN2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures
cN2b
Metastases only in clinically detected* ipsilateral internal mammary nodes and in the absence of
clinically evident level I, II axillary lymph node metastases
cN3a Metastases in ipsilateral infraclavicular lymph node(s)
cN3b Metastases in ipsilateral internal mammary lymph node(s) and axillary lymph node(s
cN3c Metastases in ipsilateral supraclavicular lymph node(s)
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pN Characteristics
pNX
Regional lymph nodes cannot be assessed (for example, previously removed, or not removed for
pathologic study)
pN0 No regional lymph node metastasis identified histologically
pN0(i−) No regional lymph node metastases histologically, negative IHC
pN0(i+) Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&E or IHC including ITC)
pN0(mol−) No regional lymph node metastases histologically, negative molecular findings (RT-PCR)
pN0(mol+)
Positive molecular findings (RT-PCR)**, but no regional lymph node metastases detected by histology
or IHC
pN1mi Micrometastases (greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm)
pN1a Metastases in 1–3 axillary lymph nodes, at least one metastasis greater than 2.0 mm
pN1b
Metastases in internal mammary nodes with micrometastases or macrometastases detected by
sentinel lymph node biopsy but not clinically detected
pN1c
Metastases in 1–3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or
macrometastases detected by sentinel lymph node biopsy but not clinically detected
pN2a Metastases in 4–9 axillary lymph nodes (at least one tumour deposit greater than 2.0 mm)
pN2b
Metastases in clinically detected internal mammary lymph nodes in the absence of axillary lymph node
metastases
pN3a
Metastases in 10 or more axillary lymph nodes (at least one tumour deposit greater than 2.0 mm); or
metastases to the infraclavicular (level III axillary lymph) nodes
pN3b
Metastases in clinically detected ipsilateral internal mammary lymph nodes in the presence of one or
more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary
lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but
not clinically detected
pN3c Metastases in ipsilateral supraclavicular lymph nodes
M Characteristics
M0 No clinical or radiographic evidence of distant metastases
cM0(i+)
No clinical or radiographic evidence of distant metastases, but deposits of molecularly or
microscopically detected tumour cells in circulating blood, bone marrow, or other nonregional nodal
tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases
M1
Distant detectable metastases as determined by classic clinical and radiographic means and/or
histologically proven larger than 0.2 mm
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Clinicopathological characteristics of breast cancers treated in a hospital: is 
screening having an impact? 
 
Informação geral:  
1.Número de formulário: ___________________________________________________________________  
2.Data de nascimento…………………..………..……………………………………………..… |__|__|/|__|__|/|__|__|__|__|  
3.Data de diagnóstico …………………………………..……………………………………………………....… |__|__|/|__|__|/2011 
4.Localização topográfica primária ……………………………………………………..…………………………………..……. C50.|__| 
5.Morfologia …………………………………………………………………………..….……………………………...….….. |__|__|__|__| 
6.Comportamento (3 – maligno) ………………………………………………………………………………………………………….…..….3 
7.Grau (1- Grau 1, bem diferenciado; 2- Grau 2, moderadamente diferenciado; 3- Grau 3, pouco 
diferenciado; 4- Grau 4, indiferenciado /anaplásico; 9- desconhecido) ………...…………………………….………… |__| 
8.Base de diagnóstico (1 - microscópico (histologia de um tumor primário, citologia, histologia de uma 
metástase)) …………………………………………………………………..……………………………………………….………………………….. 1 
9.Tumor múltiplo, se aplicável (colocar o número a que corresponde o tumor em estudo) ……….…………..….. 1  
 
Comorbilidades:  
10.Índice de Charlson (entre 0 e 90) ……………………………………………………………….………………………..…..… |__|__| 
11.Enfarte do miocárdio (1-sim; 2-não; 9-desconhecido) ………………………………….………..………………………… |__| 
12.Insuficiência cardíaca congestiva (1-sim; 2-não; 9-desconhecido) ………...….………………………….………..… |__| 
13.Doença vascular periférica (1-sim; 2-não; 9-desconhecido) ……………….….……………………………….….…..… |__| 
14.Doença cerebrovascular (1-sim; 2-não; 9-desconhecido) ………………..…….………………….…………….……..… |__| 
15.Demência (1-sim; 2-não; 9-desconhecido) .…………….………………………………………………………….…………..… |__| 
16.Doença pulmonar obstrutiva crónica (1-sim; 2-não; 9-desconhecido) ………….………………………………..… |__| 
17.Doença do tecido conjuntivo/ doença reumatológica (1-sim; 2-não; 9-desconhecido) ……………….....… |__| 
18.Úlcera péptica (1-sim; 2-não; 9-desconhecido) …………….……………………………….……………….……………...… |__| 
19.Doença hepática ligeira (1-sim; 2-não; 9-desconhecido) ……….…………………………………………..………….…. |__| 
20.Diabetes sem lesão nos órgãos (1-sim; 2-não; 9-desconhecido) ………….….………………………..……………… |__| 
21.Hemiplegia/Paraplegia (1-sim; 2-não; 9-desconhecido) ………….…………………………….….……………..………. |__| 
22.Doença renal moderada ou severa (1-sim; 2-não; 9-desconhecido) …….………………..……….………..………. |__| 
23.Diabetes com lesão nos órgãos (1-sim; 2-não; 9-desconhecido) ……………….……………………………………. |__| 
24.Outro Tumor sólido maligno sem metástases (1-sim; 2-não; 9- desconhecido)…….………………………..… |__| 
25.Linfoma (1-sim; 2-não; 9-desconhecido) ………………………………………….….……………………………….………..… |__| 
26.Leucemia (1-sim; 2-não; 9-desconhecido) ………………………………………………..……….…………………………..… |__| 
27.Doença hepática moderada ou severa (1-sim; 2-não; 9-desconhecido) ……...…………………….…………..… |__| 
28.Tumor sólido metastático (1-sim; 2-não; 9-desconhecido) …………………………………………………………….… |__| 
29.SIDA/HIV (1-sim; 2-não; 9-desconhecido) …………………………………………………………………………….…..……… |__| 
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30.Fumador (1- sim, atualmente; 2- sim, anteriormente; 3- não, nunca; 9- desconhecido) ………………….…|__| 
31.IMC à data de diagnóstico ou à data do primeiro tratamento …….……………………….…………..… |__|__|,|__|  
 
Nível de desempenho  
32.Tipo de escala do nível de desempenho (1- ECOG; 9- não disponível) …………………………………….………… |__| 
33.Score do nível de desempenho …………………………..…………….………………………………………………..… |__|__|__|  
 
Follow-up  
34.Recidiva (0- sem recidiva; 1- recidiva local; 2- recidiva em nódulos regionais ou tecidos/órgãos 
adjacentes; 3- metástases à distância; 9- desconhecido) ………….…………………….…………………………………..… |__| 
35.Data da recidiva ……..…………………………………………………….…..……………..… |__|__|/|__|__|/|__|__|__|__| 
36.Topografia do segundo tumor ………………………………………………………………………..……………..… C|__|__|.|__| 
37.Data de Incidência do segundo tumor…………….………………………………..… |__|__|/|__|__|/|__|__|__|__| 
38.Estado vital à data do último contacto (1- vivo; 2- falecido) ..……….…….………………………..………………..… |__| 
39.Causa de morte …………….………………………………………………….……..……………………____________________ 
40.Data do último contacto……………………………………….….……….……………...… |__|__|/|__|__|/|__|__|__|__|  
 
Outras informações  
41.Estado da menopausa à data de diagnóstico (1- pré-menopausa ou peri-menopausa; 2- pós menopausa; 
9- desconhecido) ………………………..……….………………………………………………….………………………………………….… |__| 
42.Modalidade de diagnóstico (0- rastreio LPCC; 1- tumor sintomático; 2- rastreio oportunista) 
…………………………………………………………..…………………………..…………………………………………………………..….…..… |__| 
43.Lateralidade (1- esquerda; 2- direita; 9- desconhecido)……………………….………………………………………….… |__| 
44.Multifocalidade (1- sim; 2- não; 9- desconhecido) ………………………..……………………………..…………………… |__|  
 
Exames de diagnóstico (até 3 meses antes ou após o diagnóstico)  
45.Mamografia (1- sim; 2- não; 9- desconhecido) …………….……………………….…………..…………………….……..… |__| 
46.Data da mamografia …………….…………………………………………………………..….|__|__|/|__|__|/|__|__|__|__| 
47.Ecografia Mamária (1- realizada; 2- não realizada; 9- desconhecido) …………..……..….………….…………..…|__| 
48.Biópsia (1- realizada; 2- não realizada; 9- desconhecido) …………………………………………………………….…….|__| 
49.Ressonância magnética (1- realizada; 2- não realizada; 9- desconhecido)……………….…………………..…....|__| 
50.Extemporâneo (1- realizado; 2- não realizado; 9- desconhecido)………………………………..…………...………..|__|  
 
 
Imagiologia para deteção de metástases (até 3 meses antes ou após o diagnóstico)  
51.No fígado (1- realizado; 2- não realizado; 9- desconhecido)……………..…………………….………………………... |__| 
52.No pulmão (1- realizado; 2- não realizado; 9- desconhecido) …………….…………..……….……………………..… |__| 
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53.No cérebro (1- realizado; 2- não realizado; 9- desconhecido) ………………………………….……………………..… |__| 
54.Nos ossos (1- realizado; 2- não realizado; 9- desconhecido)…….…………..…………………………………..…...… |__|  
 
Estadio ao diagnóstico  
55.pT (XX; 0; is; 1; 1m (T1mic); 1a; 1b; 1c; 2; 3; 4; 4a; 4b; 4c; 4d; 99- não disponível) ……….……….….… |__|__| 
56.cT (XX; 0; is; 1; 1m (T1mic); 1a; 1b; 1c; 2; 3; 4; 4a; 4b; 4c; 4d; 99- não disponível) ……….………..….… |__|__| 
57.Diâmetro patológico do tumor, em mm ……………………………………………………….………………………. |__|__|__| 
58.Diâmetro clínico do tumor, em mm .………………………………………………………………..…………….…..… |__|__|__| 
59.pN (XXX; 0; 1; 1m (N1mic); 1a; 1b; 1c; 2; 2a; 2b; 3; 3a; 3b; 3c; +++ (N+NOS); 999- não disponível) 
…………………………………..……………………….…………….…………………………………………………………………......|__|__|__| 
60.cN (XXX; 0; 1; 2; 2a; 2b; 3; 3a; 3b; 3c; +++ (N+NOS); 999- não disponível) ……..……………..….|__|__|__| 
61.Determinação (imunohistoquímica ou outra) de micrometástases ganglionares (0- não realizado; 1- 
realizado, negativo (pN0 micr); 2- realizado, positivo (pN1 micr); 3- realizado, desconhecido (pNX micr); 9- 
desconhecido) …………………………………………………………………………………………………………………..………….…….… |__|  
62.Nº total de gânglios examinados …………………………….………………………………………………………….…. |__|__|__| 
63.Nº total de gânglios metastáticos …………………………………………………………………………………….…….|__|__|__| 
64.pM (0-M0; 1-M1; 999 - não disponível) ………………………………………………...……………..………………..|__|__|__| 
65.cM (0- M0; 1- M1; 9- não disponível) ………………………………………………………….…………………….……………….|__| 
66.Local das metástases _______________________________________________________________ 
67.Biópsia de gânglio sentinela (1- realizado; 2- não realizado; 9- desconhecido).…………………….………..… |__| 
68.Nº de gânglios sentinela examinados………………………………………………………………………..………………… |__|__| 
69.Nº de gânglios sentinela positivos …………………………………………………………………………………….………....|__|__| 
70.Estadio pN do gânglio sentinela (0- N0; 1- N1; 9- NX) …………..………..………….…………………………………..… |__| 
71.Esvaziamento axilar após gânglio sentinela (1- realizado; 2- não realizado; 9- desconhecido) …….….… |__|  
 
Estado hormonal  
72.Receptores de estrogéneo (ER): percentagem/intervalo de percentagens de células positivas (caso não 
tenha este valor: 777 = teste não realizado; 888 = teste realizado mas resultado não disponível; 999 = 
desconhecido) ………………………………….....……….……………………………………………...…..… |__|__|__| - |__|__|__| 
73.Positividade ER, a preencher apenas se a percentagem de células não estiver disponível (1- positivo; 2- 
negativo; 9- desconhecido) …………..…………………………………...……………………………………………………………..… |__| 
74.Cut-off para a positividade ER ……………………………………….………………………………………………………………….....1% 
75.Receptores de progesterona (PR): percentagem/intervalo de percentagens de células positivas (caso não 
tenha este valor: 777 = teste não realizado; 888 = teste realizado mas resultado não disponível; 999 = 
desconhecido) …………………….………………………………………………………………...…..………... |__|__|__| - |__|__|__| 
76.Positividade PR, a preencher apenas se a percentagem de células não estiver disponível (1- positivo; 2- 
negativo; 9- desconhecido) ……………………………………………….………………...………………………….………………..… |__| 
77.Cut-off para a positividade PR …………………………………………………………………………………………………………1% 
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78.Ki67 (ou outro marcador de proliferação celular): percentagem/intervalo de percentagens de células 
mitóticas (caso não tenha este valor: 777 = teste não realizado; 888 = teste realizado mas resultado não 
disponível; 999 = desconhecido) ………………………………..………….………………........…..… |__|__|__| - |__|__|__| 
79.Positividade Ki67, a preencher apenas se a percentagem de células não estiver disponível (1- elevado; 2- 
baixo; 9- desconhecido) …………………………………..………………..………………………….…….……………………………..… |__| 
80.Cut-off para a positividade Ki67 …………………………………………….……………….…………………………………………30% 
81.HER2 (0- não realizado; 1- 0 (negativo); 2- 1+ (negativo); 3- 2++; 4- 3+++ (positivo); 9- desconhecido) 
……………………………………………………………………………………………………………………………………………………….…...… |__| 
82.FISH (0- não realizado; 1- realizado, positivo; 2- realizado, negativo; 3- realizado, resultado 
desconhecido; 9- desconhecido) …………………………………………………………………………….…………………………..… |__| 
83.Percentagem/intervalo de percentagens HER2 (caso não tenha este valor: 777 = teste não realizado; 888 
= teste realizado mas resultado não disponível; 999 = desconhecido) 
…………………….………………...………………………………………………………………………………....… |__|__|__| - |__|__|__| 
84.Cut-off para HER2 ……………………………………………………………………………………………………………………………...30% 
 
Tratamentos 
85.Cirurgia (0- não realizado; 1- cirurgia conservadora (quadrantectomia, nodulectomia, resseção); 2- 
mastectomia; 3- realizado, mas tipo de cirurgia desconhecido; 9- desconhecido) ……………………………...… |__| 
86.Data da cirurgia …………...…………………………………………………………………..… |__|__|/|__|__|/|__|__|__|__| 
87.Motivos para a não realização de cirurgia (1- contraindicações médicas; 2- recusa do doente; 3- cancro 
em estado avançado; 4- outro; 8- não há indicação; 9- desconhecido) …………………….…………..…………….… |__| 
88.Resultado da cirurgia (1- R0, sem tumor residual; 2- R1, tumor residual microscópico; 3- R2, tumor 
residual macroscópico; 4- tumor residual, desconhecido se R1 ou R2; 9- RX, presença de tumor residual não 
pode ser avaliada ou informação não está disponível) ……………………………………………....………………………... |__| 
89.Reconstrução (1-sim; 2-não; 9-desconhecido) …………….………..….……………………………….…………………..… |__| 
90.Data da reconstrução………………………….………………….………………………...… |__|__|/|__|__|/|__|__|__|__| 
91.Quimioterapia (QT) (1- realizado; 2- não realizado; 9- desconhecido) ...…………….…………………………..… |__| 
92.Data de início da QT …………..……………………………..…………………….…..…..… |__|__|/|__|__|/|__|__|__|__| 
93.Modalidade de QT (1- neo-adjuvante; 2- adjuvante; 3- paliativa; 9- desconhecido) ……………….…..….… |__| 
94.Tipo de QT (1- antraciclinas (±CMF); 2- taxanos (±CMF); 3- antraciclinas+taxanos (±CMF); 4- apenas CMF 
(cyclophosphamide, methotrexate e fluorouracil); 3- outras combinações; 9- desconhecido) ………………. |__| 
95.Conclusão do tratamento (1- sim; 2- não/interrupção; 9- desconhecido)….……………………….…………..… |__| 
96.Motivos para a não realização de QT (1- contraindicações médicas; 2- recusa do doente; 3- outro; 8- não 
há indicação; 9- desconhecido) …………………………….……………..…….….……………………………..…………….……..… |__| 
97.Tratamento endócrino (TE) (1- realizado; 2- não realizado; 9- desconhecido) …………………........……..… |__| 
98.Data de início do TE …………….………………….....………………….….………..…..… |__|__|/|__|__|/|__|__|__|__| 
99.Tipo de TE (1- tamoxifeno; 2- inibidores de aromatase; 3- outro; 9- desconhecido) …….………….……..… |__| 
100.Motivos para a não realização de TE (1- contraindicações médicas; 2- recusa do doente; 3- outro; 8- não 
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há indicação; 9- desconhecido) ………….…………….…………………………..…….………………..…………………………..… |__| 
101.Tratamento alvo - TA (1- realizado; 2- não realizado; 9- desconhecido)………….………………………………..|__| 
102.Data de início do TA ………………………………….………….………………………..… |__|__|/|__|__|/|__|__|__|__| 
103.Radioterapia (RT) (1- realizado; 2- não realizado; 9- desconhecido) ………………..…………………………..… |__| 
104.Data de início da RT …………….…………….……………..………….………………..… |__|__|/|__|__|/|__|__|__|__| 
105.Modalidade de RT (1- neo-adjuvante; 2- adjuvante; 3- paliativa; 9- desconhecido) ………………...…..… |__| 
106.Motivos para a não realização de RT (1- contraindicações médicas; 2- recusa do doente; 3- outro; 8- não 
há indicação; 9- desconhecido) …………………...………………….……………….………………...…………………..….………….|__| 
 
Estadio após tratamento neo-adjuvante (se aplicável)  
107.ypT (XX; 0; is; 1; 1m (T1mic); 1a; 1b; 1c; 2; 3; 4; 4a; 4b; 4c; 4d; 99- não disponível) ………………..… |__|__| 
108.ypN (XXX; 0; 1; 1m (N1mic); 1a; 1b; 1c; 2; 2a; 2b; 3; 3a; 3b; 3c; +++ (N+NOS); 999- não disponível) 
……………………..………………………………………………….…………………………………………………………………….… |__|__|__| 
109.yM (0- M0; 1- M1; 9- não disponível) …………………….……..…….………………………………………….……………….|__|  
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